Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system

Liver Transplantation

Volumn 14, Issue 4, 2008, Pages 526-533

  Adler, Michael ^a   De Pauw, Filip ^b   Vereerstraeten, Pierre ^a   Fancello, Agnese ^a   Lerut, Jan ^c   Starkel, Peter ^c   Van Vlierberghe, Hans ^d   Troisi, Roberto ^d   Donckier, Vincent ^a   Detry, Olivier ^e   Delwaide, Jean ^e   Michielsen, Peter ^b   Chapelle, Thierry ^b   Pirenne, Jacques ^f   Nevens, Frederik ^f  

^a ERASME HOSPITAL   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BELGIUM; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PLANNING; HIGH RISK POPULATION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; RECURRENCE RISK; SURGICAL MORTALITY; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; EUROPE; FEMALE; HEALTH CARE RATIONING; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SELECTION; RESOURCE ALLOCATION; WAITING LISTS;

EID: 42149092189     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21399     Document Type: Article

References (44)

1. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2005;128:1752-1764.
2. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
3. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002;8:765-774.
4. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004;127:S261-S267.
5. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004;10:36-41.
6. Eurotransplant Newsletter 2003;189:5.
7. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
8. Majno P, Giostra E, Morel P, Hadengue A, Mentha G; Geneva Liver Cancer Study Group. Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol 2005;42:S134-S143.
9. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649.
10. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, et al. Model for End-Stage Liver Disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-96.
11. United Network for Organ Sharing. Available at: http://www.unos.org. Accessed December 5, 2007.
12. Yao FY, Bass NM, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl 2004;10:621-630.
13. Liver (including intrahepatic bile ducts). In: Green FL, Page DL, Fleming ID, American Joint Committee on Cancer, American Cancer Society, eds. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002:131-144.
14. Edmonson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48.900 necropsies. Cancer 1954:7:462-503.
15. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1984.
16. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997;16:965-980.
17. Abacus concepts. Survival tools for Stat View. Berkeley, CA: Abaccus Concepts; 1994.
18. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999:30: 1434-1440.
19. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wut V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883.
20. Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, Gores G. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004;10:449-455.
21. Roayaie S, Llovet JM. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified? Clin Liver Dis 2005;9:315-328.
22. Yamashiki N, Gaynor JJ, Kato T, Reddy KR, Sobhonslidsuk A, Levi D, et al. Competing risks analysis of predictors of delisting owing to tumour progression in liver transplant candidates with hepatocellular carcinoma. Am J Transplant 2004;4:774-781.
23. Fisher RA, Maluf D, Cotterell AH, Stravitz T, Wolfe L, Luketic V, et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004;18:502-512.
24. Ravaioli M, Grazi GL, Ballardini G, Cavrini G, Ercolani G, Cescon M, et al. Liver transplantation with the MELD system: a prospective study from a single European center. Am J Transplant 2006;6:1572-1577.
25. Huo TI, Wu JC, Lin HC, Lee FY, Hou MC, Hunag YH, et al. Determination of the optimal Model for End-Stage Liver Disease score in patients with small hepatocellular carcinoma undergoing loco-regional therapy. Liver Transpl 2004;10:1507-1513.
26. Degre D, Bourgeois N, Boon N, Le Moine O, Louis H, Donckier V, et al. Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation. Transpl Int 2004;17:31-38.
27. Everson GT. MELD: the answer or just more questions? Gastroenterology 2003;124:251-254.
28. Olthoff KM, Brown RS Jr, Delmonico FL, Freeman RB, McDiarmid SV, Merion RM, et al. Summary report of a national conference: evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl 2004;10:A6-A22.
29. Libbrecht L, Bielen D, Verslype C, Vanbeckevoort D, Pirenne J, Nevens F, et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pre-transplantation imaging examinations. Liver Transpl 2002;8:749-761.
30. Freeman RB, Mithoefer A, Ruthazer R, Nguyen K, Schore A, Harper A, Edwards E. Optimizing staging for hepatocellular carcinoma before liver transplantation: a retrospective analysis of the UNOS/OPTN database. Liver Transpl 2006;12:1504-1511.
31. Caturelli E, Solmi L, Anti M, Fusilli S, Roselli P, Andriulli A, et al. Ultrasound guided fine needle biopsy of early hepatocellular carcinoma complicating liver cirrhosis: a multicentre study. Gut 2004;53:1356-1362.
32. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma Gastroenterology 2004;127:S179-S188.
33. Otto G, Herber S, Heise M, Lohse AW, Monch C, Bittinger F, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006;12:1260-1267.
34. Adam R, Azoulay D, Castaing D, Eshkenazy R, Pascal G, Hashizume K, et al. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy? Ann Surg 2003;238:508-518.
35. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumour seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-1129.
36. Bruix J, Llovet JM. Prognostic prediction and treatment strategies in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
37. Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918.
38. Herrero JI, Sangro, B, Quiroga J, Pardo F, Herraiz M, Cienfuegos JA, Prieto J. Influence of tumour characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001;7:631-636.
39. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multi-center study. Liver Transpl 2004;10:1343-1354.
40. Vauthey JN, Ribero D, Abdalla EK, Jonas S, Bharat A, Schumacher G, et al. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J Am Coll Surg 2007;204:1016-1027.
41. Busuttil RW, Farmer DG, Yersiz H, Hiatt JR, McDiarmid SV, Goldstein LI, et al. Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg 2005;241:905-916.
42. Bruix J, Llovet JM. Prognostic prediction in HCC: did anyone expected to be easy? Hepatology 2004;39:551-552.
43. Marsh JW, Casavilla A, Iwatsuki S, Dvorchik I, Subotin M, Balan V, et al. Predicting the risk of tumor recurrence following transplantation for hepatocellular carcinoma. Hepatology 1997;26:1689-1691.
44. Vivarelli M, Cucchetti A, Piscaglia F, La Barba G, Bolondi L, Cavallari A, Pinna AD. Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression. Liver Transpl 2005;11:497-503.